Prana to Present at New York Academy of Science Symposium on

Prana to Present at New York Academy of Science Symposium on November
29th 
"Targeting Metals in Alzheimer's and Other Neurodegenerative
Diseases" 
MELBOURNE, AUSTRALIA -- (Marketwire) -- 11/20/12 --   Prana
Biotechnology (NASDAQ: PRAN) (ASX: PBT) today announced that the New
York Academy of Science is hosting a symposium on November 29th
titled "Targeting Metals in Alzheimer's and Other Neurodegenerative
Diseases." Dr. Rudy Tanzi, the Joseph P. and Rose F. Kennedy
Professor of Neurology at Harvard University and Prana's Chief
Scientific Advisor, and Dr. Robert Cherny, Prana's Head of Research,
will take part in the symposium. The presentations will explore the
causative events leading to the neuropathology that drives
Alzheimer's disease, Parkinson's disease and Huntington disease. This
symposium will examine how these findings led to the discovery of
small molecules designed to restore the balance of transition metals
in the brain that are critical for neuronal function, reduce the
accumulation of aggregated target proteins, and could have a
disease-modifying effect. A review of Prana's PBT2 clinical history
will be presented.  
Dr. Tanzi said, "Researchers are increasingly focusing on the role of
metals in neurodegenerative disease, providing data that promotes
optimism for the outcome of Prana's trials. As we learn more about
the genetics of Alzheimer's disease it appears that the disease is
triggered by the excessive accumulation of the amyloid beta protein
in the brain. Prana's therapeutic strategy for treating
neurodegenerative disease involves a very different mechanism of
action than that of other anti-beta-amyloid drugs, which have largely
failed." 
The symposium is presented by the Brain Dysfunction Discussion Group
at the New York Academy of Sciences and is free for Academy members.
Both members and non-members can register to attend the symposium or
tune in via the live webinar at www.nyas.org/MetalsandAD (register
free from Monday 26 Nov). Media should RSVP to Diana Friedman at
dfriedman@nyas.org. 
ASIC Granted Postponement of AGM until 12th December 2012 
In accordance with Section 250P of the Corporation Act of 2001, Prana
has been granted Australian Securities and Investment Commission
(ASIC) approval to hold the 2012 Annual General 
Meeting on December
12, 2012 in order to enable Geoffrey Kempler, Chairman of Prana, to
participate in the New York Academy of Science meeting on November
29th to discuss Prana and its scientific research.  
About Prana Biotechnology Limited
 Prana Biotechnology was
established to commercialize research into age-related
neurodegenerative disorders. The Company was incorporated in 1997 and
listed on the Australian Securities Exchange in March 2000 and listed
on NASDAQ in September 2002. Researchers at prominent international
institutions including The University of Melbourne, The Mental Health
Research Institute (Melbourne) and Massachusetts General Hospital, a
teaching hospital of Harvard Medical School, contributed to the
discovery of Prana's technology.  
For further information please visit the Company's web site at
www.pranabio.com. 
About the New York Academy of Sciences
 The New York Academy of
Sciences is an independent, not-for-profit organization committed to
advancing science, technology, and society worldwide since 1817. With
25,000 members in 140 countries, the Academy is creating a global
community of science for the benefit of humanity. The Academy's core
mission is to advance scientific knowledge, positively impact the
major global challenges of society with science-based solutions, and
increase the number of scientifically informed individuals in society
at large. Visit www.nyas.org for more information on the Academy.  
Forward Looking Statements  
This press release contains "forward-looking statements" within the
meaning of section 27A of the Securities Act of 1933 and section 21E
of the Securities Exchange Act of 1934. The Company has tried to
identify such forward-looking statements by use of such words as
"expects," "intends," "hopes," "anticipates," "believes," "could,"
"may," "evidences" and "estimates," and other similar expressions,
but these words are not the exclusive means of identifying such
statements. Such statements include, but are not limited to any
statements relating to the Company's drug development program,
including, but not limited to the initiation, progress and outcomes
of clinical trials of the Company's drug development program,
including, but not limited to, PBT2, and any other statements that
are not historical facts. Such statements involve risks and
uncertainties, including, but not limited to, those risks and
uncertainties relating to the difficulties or delays in financing,
development, testing, regulatory approval, production and marketing
of the Company's drug components, including, but not limited to,
PBT2, the ability of the Company to procure additional future sources
of financing, unexpected adverse side effects or inadequate
therapeutic efficacy of the Company's drug compounds, including, but
not limited to, PBT2, that could slow or prevent products coming to
market, the uncertainty of patent protection for the Company's
intellectual property or trade secrets, including, but not limited
to, the intellectual property relating to PBT2, and other risks
detailed from time to time in the filings the Company makes with
Securities and Exchange Commission including its annual reports on
Form 20-F and its reports on Form 6-K. Such statements are based on
management's current expectations, but actual results may differ
materially due to various factions including those risks and
uncertainties mentioned or referred to in this press release.
Accordingly, you should not rely on those forward-looking statements
as a prediction of actual future results. 
Contacts: 
Australia
Prana Biotechnology
+61 3 9349 4906 
US
Leslie Wolf-Creutzfeldt
T: 646-284-9472
E: leslie.wolf-creutzfeldt@grayling.com 
 
 
Press spacebar to pause and continue. Press esc to stop.